PDGFRA exon 18 mutation
1 drugsPredictive biomarker for patient selection in 6 indications
1
Approved Drugs
6
Indications
1
Companies
PDGFRA exon 18 mutation is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 6 indications including Gastrointestinal Stromal Tumor, Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis. Explore the targeted therapies, indications, testing methods, and companies developing PDGFRA exon 18 mutation drugs below.
Search PDGFRA exon 18 mutation Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PDGFRA exon 18 mutation
| Drug | Company | Therapeutic Area |
|---|---|---|
| AYVAKIT | BLUEPRINT MEDICINES | Oncology |
PDGFRA exon 18 mutation Indications
Gastrointestinal Stromal Tumor Advanced Systemic Mastocytosis Aggressive Systemic Mastocytosis Systemic Mastocytosis with Associated Hematological Neoplasm Mast Cell Leukemia Indolent Systemic Mastocytosis